Search

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.54 -2.48

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.5

Max

3.71

Pagrindiniai rodikliai

By Trading Economics

Pajamos

8.3M

-18M

Pardavimai

9.6M

10M

P/E

Sektoriaus vid.

22.5

60.149

Pelnas, tenkantis vienai akcijai

-0.1

Pelno marža

-177.89

Darbuotojai

69

EBITDA

9.5M

-18M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+226.8% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-91M

819M

Ankstesnė atidarymo kaina

6.02

Ankstesnė uždarymo kaina

3.54

Naujienos nuotaikos

By Acuity

60%

40%

284 / 340 reitingas Healthcare

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-20 23:56; UTC

News

Brookdale Senior Living announced its second-quarter 2026 earnings release dates, boosting investor sentiment. Shares are trading higher in after-market hours.

2026-07-20 23:56; UTC

News

Valero Energy Corp gains in after-market trading on strong earnings forecast, with projected EPS of $9.81 and revenue expectations of $35.95 billion.

2026-07-20 23:51; UTC

News
Correlated Moves

Ally Financial shares are lower in after-market trading despite the board declaring a quarterly cash dividend of $0.30 per share.

2026-07-20 23:51; UTC

Social Media
News

Magnolia Oil & Gas announced a $1 billion stock offering to fund the acquisition of WildFire Intermediate Holdings, resulting in a sharp decline in after-market hours.

2026-07-20 23:46; UTC

News

Advanced Energy Industries gained after-market hours following $31 million in funding for the Idaho Advanced Energy Consortium's Nuclear Energy Corridor Tech Hub initiative.

2026-07-20 23:46; UTC

News

Ross Stores announced 47 new locations but shares are trading lower in after-market hours following Monday's close. The company plans to open about 110 stores in 2026.

2026-07-20 23:46; UTC

News

Monarch Casino & Resort Inc reports record Q2 revenue of $142.6 million and EPS of $1.78, trading higher in after-market hours.

2026-07-20 23:46; UTC

News

Sweetgreen Inc shares are higher in after-market trading, despite ongoing concerns in the restaurant sector over a cyclospora outbreak linked to iceberg lettuce.

2026-07-20 23:46; UTC

News

Warner Bros Discovery shares are lower in after-market hours as a judge pauses the $110 billion Paramount Skydance acquisition, extending legal uncertainty.

2026-07-20 23:41; UTC

News
Event

Calix Inc's stock is lower in after-market trading following a mixed earnings report and a disappointing third-quarter outlook, alongside a class action lawsuit.

2026-07-20 23:36; UTC

News

GameStop shares are lower in after-market hours as the company proposes a stock-based acquisition of eBay, introducing significant new debt and operational changes.

2026-07-20 23:36; UTC

News
Correlated Moves

Invesco Ltd's shares rose during after-market hours, reflecting a modest increase since Monday's close, alongside gains in the Invesco S&P 500 High Dividend Low Volatility ETF.

2026-07-20 23:36; UTC

News

Jazz Pharmaceuticals PLC will report second-quarter results on August 3, contributing to positive investor sentiment as shares trade higher after market hours.

2026-07-20 23:32; UTC

News

Broadcom Inc. shares are higher in after-hours trading, driven by strong historical returns and potential growth from Meta Platforms' AI chip production plans.

2026-07-20 23:26; UTC

News
Correlated Moves

Blackstone Inc. shares are higher in after-market trading following a $676 million investment in South Korea's Futronic, enhancing its technology portfolio.

2026-07-20 23:16; UTC

News

Enphase Energy shares fell after TD Cowen cut its price target from $70 to $48, citing a challenging solar market and weaker demand. The stock was roughly flat in after-market trading.

2026-07-20 23:16; UTC

News
Social Media

Alphabet Inc shares are higher in after-market hours as reports reveal plans for a new AI chip that may significantly outperform current models.

2026-07-20 23:16; UTC

News

Quanta Services reported a $48 billion backlog, signaling strong revenue potential. Shares moved higher in after-market hours amid bullish analyst sentiment.

2026-07-20 23:06; UTC

News

ServiceNow Inc. shares are trading lower in after-market hours amid bearish sentiment over potential disruptions from generative AI and rising Treasury yields.

2026-07-20 23:06; UTC

News

Pomerantz LLP has filed a class action lawsuit against Lucid Group Inc, alleging securities fraud related to misleading statements about operational capabilities and performance.

2026-07-20 23:06; UTC

News
Social Media

General Electric Co advances in aviation technology with a hybrid-electric flight demonstration and secures an engine deal with Philippine Airlines, shares higher after-market.

2026-07-20 23:06; UTC

News

Geopolitical tensions, particularly between the U.S. and Iran, have impacted global consumer sentiment. Nike shares were little changed during after-market hours.

2026-07-20 23:06; UTC

News

Yum Brands Inc shares declined after a report of reduced foot traffic at Taco Bell due to a parasite outbreak linked to lettuce supplied by a vendor.

2026-07-20 23:02; UTC

News

Zions Bancorporation NA reported Q2 earnings of $452 million, or $3.05 per share, but shares are lower in after-market trading amid mixed results.

2026-07-20 23:02; UTC

News

W. R. Berkley Corporation reported strong second-quarter earnings but missed revenue expectations. Shares declined during after-market hours amid notable volatility.

2026-07-20 23:01; UTC

News

Coca-Cola Consolidated Inc shares rose during after-market hours, reflecting positive sentiment in the beverage sector despite earlier session volatility.

2026-07-20 23:01; UTC

News

Karyopharm Therapeutics shares fell in after-market hours following the announcement of a leadership cash retention program aimed at key executives.

2026-07-20 23:01; UTC

Social Media
News

Park Aerospace Corp reported first-quarter earnings of $0.17 per share, exceeding estimates, and is trading higher in after-market hours.

2026-07-20 23:01; UTC

News
Event

Cracker Barrel completed a sale-leaseback for 26 locations, generating $77 million. Shares are trading higher after exceeding previous revenue guidance.

2026-07-20 23:01; UTC

News
Social Media
Event

Crown Holdings reported second-quarter adjusted EPS of $2.49, exceeding estimates. The company raised its full-year EPS guidance, with shares higher in after-market hours.

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

226.8% į viršų

12 mėnesių prognozė

Vidutinis 11.83 USD  226.8%

Aukščiausias 16 USD

Žemiausias 6 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

284 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
help-icon Live chat